Diskussion zur BICO Group Aktie WKN: A2PX00 ISIN: SE0013647385 Forum: Aktien User: Hedgehog3

Bei 5€ wird das Ding abgeworfen. Da hilft nur noch eine Übernahme

am 09.01.2023 war er bei 10,-€!

Puh, also das irritiert mich total obwohl ich jetzt gut 2 Jahre hier dabei bin. Frage mich, wann der Kurs jemals wieder 10€ erreicht.

Hoffe die fallen nochmal auf 3€, dann würde ich gerne nachkaufen.

EBITDA von Bioprinting scheint mir gesünder als die Bioautomation Werte.

Publication of BICO Group Year-end report 2023 October-December 2023 (compared with October-December 2022) Net sales amounted to SEK 636.6m (665.9) which corresponds to a decrease of 4.4% (increase of 28.3%) compared to the corresponding quarter previous year Organic sales growth for the quarter amounted to -4.4% (20.1%) The gross margin amounted to 70.2% (71.3%) Adjusted EBITDA amounted to SEK 86.1m (69.8) corresponding to a margin of 13.5% (10.5%) EBITDA amounted to SEK 95.1m (69.7) corresponding to a margin of 14.9% (10.5%) Net profit/loss for the quarter from continuing operations amounted to SEK -877.0m (-217.8) corresponding to earnings per share from continuing operations before and after dilution of SEK -12.42 (-3.29). This was affected by goodwill impairment in Group companies Cash flow from operating activities amounted to SEK 162.0m (-69.1) January-December 2023 (compared with January-December 2022) Net sales amounted to SEK 2,249.9m (2,120.8), which corresponds to an increase of 6.1% (68.7%) compared to the corresponding period previous year Organic sales growth for the period amounted to 5.8% (29.1%) The gross margin amounted to 70.1% (74.8%) Adjusted EBITDA amounted to SEK 217.7m (126.2), corresponding to a margin of 9.7% (6.0%) EBITDA amounted to SEK 360.4m (15.0) corresponding to a margin of 16.0% (0.7%) Net profit/loss for the period from continuing operations amounted to SEK -1,698.0m (-88.1) corresponding to earnings per share from continuing operations before and after dilution of SEK -24.04 (-1.33) This was affected by goodwill impairment in Group companies Cash flow from operating activities amounted to SEK 178.4m (-269.4) The Board proposes no dividend for 2023 All numbers in the Year-end report refers to continuing operations if not otherwise stated. Ginolis has been classified as discontinued operations from the fourth quarter 2023 with retroactive effect. Q4 takeaways Decline in sales due to slower market in Academia, Diagnostics, and Biotech Improved profitability and double-digit EBITDA- and adjusted EBITDA margin Maria Forss assumed office as CEO and President on November 20, 2023 Divestment of the Berlin property completed for SEK 244m (sale and leaseback with BICO company SCIENION) Agreement signed to develop lab automation solution for 28 MUSD Non-cash flow affecting goodwill impairment in group companies: SCIENION, Visikol, and Nanoscribe which amounted to SEK 582m Significant events after Q4 Catharina Nordlund appointed as Global Head of HR

Bioprinting ist halt ne Katastrophe

Wo sieht man die Zahlen ?

Zumindest teile davon

Naja überkrasse Bewertung absolut nicht aber zahlen halt mies

In welchen Punkten ist das Zahlenwerk eine Katastrophe?

Zahlenwerk ist eine Katastrophe.. dazu die überkrasse Bewertung..

Eher zurecht. Der Kurs gibt immer einem Recht

Völlig übertriebener Abverkauf, irre

Könnte auch schon zwischen 36 und 37 sek support finden, das wären so 3,18 bis 3,3 Euro ca.

2,75 € ist das Ziel